Since the primary function of CDK4/6, which is activated by the D-type cyclins D1, D2, and D3 (cyclin D), is to drive cell-cycle progression from G1 to S phase, it is believed that the major mechanism responsible for anti-tumor activity of CDK4/6 inhibitors is induction of cell cycle arrest. The gene discussed is CDK4; the disease is neoplasm.